In summary, these results suggest that CD24-Fc administration at the time of initial tumor vaccination can impair tumor immunity, but if the administration of CD24-Fc is delayed after the initial vaccination and administered with the boosters, the effect on tumor immunity induced by the vaccine does not appear to be hindered. This evidence concerns the gene CD24 and neoplasm.